Shots:

• The US FDA has granted BTD to pegloprastide (AVB-620) for the intraoperative detection and visualization of positive margins during breast cancer surgery
• Earlier- the company reported results of P-II/III study that demonstrated the use of pegloprastide during surgery correctly identified cancer in ~ 75% of patients who would have otherwise been candidates for a repeat (re-excision) surgery
• Pegloprastide is designed to deliver a fluorescent marker to cancer cells to aid surgeons in identifying positive margins in real-time during surgery

 ­ Ref: PRNewswire | Image: BioSpace